 TRACON Pharmaceuticals Inc NASDAQ:TCON announced that its undifferentiated pleomorphic sarcoma UPS drug envafolimab has been granted fast track designation by the US Food and Drug Administration. The designation covers the development of envafolimab for patients with locally advanced, unresectable or metastatic UPS and myxofibrosarcoma MFS who have progressed on one or two prior lines of chemotherapy. 